AVBP News

ArriVent BioPharma Reports Second Quarter 2025 Financial Results

NEWTOWN SQUARE, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the second quarter ended June 30, 2025, and highlighted recent Company progress.

August 11, 2025Earnings

Jones Trading Initiates Coverage On ArriVent BioPharma with Buy Rating, Announces Price Target of $40

AVBP

May 20, 2025

HC Wainwright & Co. Maintains Buy on ArriVent BioPharma, Raises Price Target to $40

AVBP

May 14, 2025

ArriVent Lead Drug Candidate Shows Promise In Lung Cancer Type, Analyst Sees Over 50% Upside

AVBP

B. Riley initiates coverage on ArriVent Biopharma, citing firmonertinib's potential in NSCLC. The analyst sees strong upside with a $37 price target.

March 20, 2025

B. Riley Securities Initiates Coverage On ArriVent BioPharma with Buy Rating, Announces Price Target of $37

AVBP

March 20, 2025

Guggenheim Initiates Coverage On ArriVent BioPharma with Buy Rating, Announces Price Target of $45

AVBP

March 10, 2025

HC Wainwright & Co. Reiterates Buy on ArriVent BioPharma, Maintains $39 Price Target

AVBP

March 7, 2025

ArriVent BioPharma 2024 Net Loss $80.5M; Cash, Cash Equivalent And Investments Of $266.5M As Of Dec. 31, 2024

AVBP

March 3, 2025

HC Wainwright & Co. Reiterates Buy on ArriVent BioPharma, Maintains $36 Price Target

AVBP

November 15, 2024

ArriVent BioPharma Q3 EPS $(0.61) Beats $(0.82) Estimate

AVBP

November 14, 2024